کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
not be forgotten. Preventive efforts to halt the progression of atherosclerotic changes in grafted veins and native coronary arteries perhaps are the better way; be that as it may, the impact of risk factor modification and changing life style on this issue needs to be confirmed with larger scale clinical trials.

References

1. Behboudi F, Vakili H, Hashemi SR. Immediate results and six-month clinical outcome after percutaneous coronary intervention in patients with prior coronary artery bypass surgery. J Teh Univ Heart Ctr 2011;6:31-36.
2. Goldman S, Zadran K, Moritz T, Ovitt T, Sethi G, Copeland JG. Long term patency of saphenous vein and internal mammary artery grafts after coronary artery bypass surgery; results from a department of veterans affairs cooperative study. J Am Coll Cardiol 2004;44:2149-2156.
3. Kereiakes DJ, Turco MA, Breall J. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions. J Am Coll Cardiol 2008;1:248-257.
4. Fitzgibbon GM, Kafka HP, Leach AJ. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388. J Am Coll Cardiol 1996;28:616-626.
5. Roffi M, Mukherjee D. Current role of emboli protection devices in percutaneous coronary and vascular interventions. Am Heart J 2009;157:263-270.
6. Kirtane AJ, Heyman ER. Correlates of adverse events during saphenous vein graft intervention with distal embolic protection, a PRIDE study. J Am Coll Cardiol 2008;1:186-191.
7. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
8. Smith SC, Jr, Feldman TE, Hirshfeld JW, Jr, Jacobs AK, Kern MJ, King SB, 3rd, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006;113:e166-286.
9. Mehta SK, Frutkin AD, Milford-Beland S, Klein LW, Shaw RE, Weintraub WS, Krone RJ, Anderson HV, Katcher MA, Marso SP, American College of Cardiology-National Cardiovascular Data Registry. Utilization of distal embolic protection in saphenous vein graft interventions. Am J Cardiol 2007;100:1114-1118.

Seyed Kianoosh Hoseini,
Assistant Professor of Cardiology,
Tehran University of Medical Sciences,
Tehran Heart Center,
Karegar Ave,
Tehran,
Iran.

Percutaneous Revascularization of Patients with History of Coronary Bypass Graft: Reply

First of all, allow me to thank you very much for your interest in our study.1

Our study was performed in a single center with a small group of patients, which may have created some bias in the prediction of adverse outcomes. In addition, the small size of the study population precluded a comparison of the outcomes between those who underwent percutaneous coronary intervention (PCI) on native coronaries and those who received intervention on saphenous vein grafts (SVGs). Nevertheless, the results of our study showed that PCI on native coronaries is more desirable than PCI on SVGs because many of our major adverse cardiac event (MACE) cases were in the SVG group.

With respect to the next question, only 5% of our SVG group cases had no distal protection devices, and there was one case of non ST-elevation myocardial infarction (NSTEMI) due to the no-reflow phenomenon after stenting a SVG on the optus marginal (OM) artery and no distal protection devices were used. Finally, we had one case of ST-elevation myocardial infarction (STEMI) due to the distal embolization in the PCI of the SVG on the OM artery despite using a distal protection device; however, no no-reflow phenomenon was observed in the native coronaries group. Studies have shown the consistent benefits of embolic protection devices, independent of glycoprotein IIb/IIIa antagonist use. Embolic protection has been established as the standard of care for SVG stenting, with a favorable cost-benefit profile.2,3 Embolic protection devices reduce the secondary phenomena of no-reflow and end organ infarction.4,7

We hope that our explanations will help the esteemed readers to better understand the views mentioned.

References

1. Behboudi F, Vakili H, Hashemi SR, Hekmat M, Safi M, Namazi MH. Immediate results and six-month clinical outcome after percutaneous coronary intervention in patients with prior coronary artery bypass surgery. J Teh Univ Heart Ctr 2011;6:31-36.
2. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial
Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.

3. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Baim DS: Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005;95:173-177.

4. Cohen DJ, Murphy SA, Baim DS, Lavelle TA, Berezin RH, Cutlip DE, Ho KK, Kuntz RE; SAFER Trial Investigators. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol 2004;44:1801-1808.

5. Carrozza JP Jr, Mumma M, Breall JA, Fernandez A, Heyman E, Metzger C; PRIDE Study Investigators. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol 2005;46:1677-1683.

6. Rogers C, Huynh R, Seifert PA, Chevalier B, Schofer J, Edelman ER, Toegel G, Kuchela A, Woupio A, Kuntz RE, Macon ND. Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation 2004;109:1735-1740.

7. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA; FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-553.

Fateme Behboudi,
Cardiologist,
Department of Cardiovascular Medicine,
Shaheed Beheshti University of Medical Sciences,
Modarres Hospital,
Tehran,
Iran.
199873438.
Tel: +98 21 22083106.
Fax: +98 21 22083106.
Email: dr_h_behboudi@yahoo.co.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله